Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 69
Filter
1.
Blood Cells Mol Dis ; 108: 102860, 2024 May 29.
Article in English | MEDLINE | ID: mdl-38889660

ABSTRACT

Acquired aplastic anemia (AA) is a rare heterogeneous disorder characterized by pancytopenia and hypoplastic bone marrow. The incidence is 2-3 per million population per year in the Western world, but 3 times higher in East Asia. Survival in severe aplastic anemia (SAA) has improved significantly due to advances in hematopoietic stem cell transplantation (HSCT), immunosuppressive therapy, biologic agents, and supportive care. In SAA, HSCT from a matched sibling donor (MSD) is the first-line treatment. If a MSD is not available, options include immunosuppressive therapy (IST), matched unrelated donor, or haploidentical HSCT. The purpose of this guideline is to provide health care professionals with clear guidance on the diagnosis and management of pediatric patients with AA. A preliminary evidence-based document prepared by a group of pediatric hematologists of the Bone Marrow Failure Study Group of the Italian Association of Pediatric Hemato-Oncology (AIEOP) was discussed, modified and approved during a series of consensus conferences that started online during COVID 19 and continued in the following years, according to procedures previously validated by the AIEOP Board of Directors.

2.
Am J Hematol ; 99(4): 534-542, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38282561

ABSTRACT

This study identifies a new chronic form of immune neutropenia in the young with or without detectable indirect anti-neutrophil antibodies, characterized by mild/moderate neutropenia low risk of severe infection (14%), tendency to develop autoimmune phenomena over the course of the disease (cumulative incidence of 58.6% after 20 years of disease duration), leukopenia, progressive reduction of absolute lymphocyte count and a T- and B-cell profile similar to autoimmune disorders like Sjogren syndrome, rheumatoid arthritis, and systemic lupus erythematosus (increased HLADR+ and CD3 + TCRγδ cells, reduced T regulatory cells, increased double-negative B and a tendency to reduced B memory cells). In a minority of patients, P/LP variants related to primary immuno-regulatory disorders were found. This new form may fit the group of "Likely acquired neutropenia," a provisional category included in the recent International Guidelines on Diagnosis and Management of Neutropenia of EHA and EUNET INNOCHRON ACTION 18233. The early recognition of this form of neutropenia would help clinicians to delineate better specific monitoring plans, genetic counseling, and potentially targeted therapies.


Subject(s)
Arthritis, Rheumatoid , Autoimmune Diseases , Lupus Erythematosus, Systemic , Neutropenia , Thrombocytopenia , Humans , Neutropenia/etiology , Neutropenia/therapy , Autoimmune Diseases/complications , Lupus Erythematosus, Systemic/complications , Thrombocytopenia/complications
3.
Radiat Prot Dosimetry ; 180(1-4): 102-108, 2018 Aug 01.
Article in English | MEDLINE | ID: mdl-29040768

ABSTRACT

The design and operation of ITER experimental fusion reactor requires the development of neutron measurement techniques and numerical tools to derive the fusion power and the radiation field in the device and in the surrounding areas. Nuclear analyses provide essential input to the conceptual design, optimisation, engineering and safety case in ITER and power plant studies. The required radiation transport calculations are extremely challenging because of the large physical extent of the reactor plant, the complexity of the geometry, and the combination of deep penetration and streaming paths. This article reports the experimental activities which are carried-out at JET to validate the neutronics measurements methods and numerical tools used in ITER and power plant design. A new deuterium-tritium campaign is proposed in 2019 at JET: the unique 14 MeV neutron yields produced will be exploited as much as possible to validate measurement techniques, codes, procedures and data currently used in ITER design thus reducing the related uncertainties and the associated risks in the machine operation.


Subject(s)
Deuterium/analysis , Neutrons , Nuclear Reactors/instrumentation , Radiation Monitoring/instrumentation , Radiation Monitoring/methods , Radiation Protection/instrumentation , Tritium/analysis , Radiation Dosage
4.
Appl Radiat Isot ; 134: 105-107, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29066213

ABSTRACT

A severe supply crisis of 99Mo, precursor of 99mTc a diagnostic radionuclide largely used in Nuclear Medicine, occurred in 2008-2009 due to repeated shut-down of the two main (aged) fission reactors. An alternative route for producing 99Mo by 100Mo(n,2n)99Mo reaction was investigated at ENEA. The experiment, designed according to Monte Carlo simulations performed with the Fluka code, produced 99Mo by irradiating a natural Molybdenum powdered target with 14MeV neutrons produced at the Frascati Neutron Generator. The 99Mo specific activity was measured at metrological level by γ-ray spectrometry.

5.
Arch Pediatr ; 24(3): 249-253, 2017 Mar.
Article in French | MEDLINE | ID: mdl-28161229

ABSTRACT

Endoscopic management is the gold standard for symptomatic low-grade vesicoureteral reflux (VUR) in children. Deflux® (hyaluronic acid/dextranomer) injection is highly effective and has very few complications. We report on two cases of secondary megaureter after Deflux® injections. In the first case, a boy presented with Grade 4 VUR. He received a bilateral Deflux® injection with a total of three syringes. The postoperative ultrasound was normal. However, a check-up ultrasound 3 years later showed a significant ureteropyelocalyceal dilatation, with stasis and decreased renal function on scintigraphy, the reason why antireflux surgery (Cohen procedure) was performed. In the second case, a girl diagnosed with bilateral VUR at birth received bilateral injections with one syringe on each side at the age of 12 months. One month later, the ultrasound showed a dilation of the distal ureters (diameter of the right ureter, up to 10mm; left ureter, up to 6.7mm). The child underwent surgery 8 months later (Cohen procedure) because of iterative pyelonephritis and persistent ureter dilatation. Only one previous case has been described in the literature. In our experience, this complication has occurred only twice in 452 injections (4‰). In conclusion, endoscopic treatment with hyaluronic acid/dextranomer injection is a minimally invasive procedure that improves the situation in cases of VUR. It has few complications. Other than failure, there is a low risk of secondary expansion requiring, in our opinion, ultrasound verification over the long term.


Subject(s)
Dextrans/adverse effects , Hyaluronic Acid/adverse effects , Ureter/drug effects , Vesico-Ureteral Reflux/therapy , Child , Child, Preschool , Cystography , Dextrans/administration & dosage , Dilatation, Pathologic/chemically induced , Dilatation, Pathologic/diagnosis , Female , Follow-Up Studies , Humans , Hyaluronic Acid/administration & dosage , Injections , Male , Ultrasonography , Ureteroscopy , Vesico-Ureteral Reflux/diagnosis
6.
Bone Marrow Transplant ; 52(7): 1022-1028, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28112743

ABSTRACT

Chemotherapy and irradiation can affect the gonads, leading to impairment of pubertal development and/or infertility. Fertility preservation (FP) is therefore a crucial endeavor in hematopoietic stem cell transplantation (HSCT) because of the severe impact of infertility on the quality of life of long-term survivors. Despite the existence of different international guidelines, FP counseling and procedures are not routinely implemented as part of patient care. We present herein a survey conducted by the Pediatric Working Party of the European Society for Blood and Marrow Transplantation (EBMT), which aims to analyze and compare different FP practices for children and adolescents across EBMT centers in 2013. A total of 177 pediatric centers reporting to the EBMT were contacted; of this number, 38 centers (21%) located in 16 different countries responded. These centers reported 834 patients receiving HSCT in 2013 (73% prepubertal), corresponding to 22% of all children (n=3789) undergoing HSCT in EBMT reporting centers. Overall, 39% of the reported patients received counseling and 29% received an FP procedure. The increased need for FP programs, extended education for patient-care teams, and more personal resources and funding emerged from this survey as pivotal factors necessary to support and implement such programs.


Subject(s)
Fertility , Hematopoietic Stem Cell Transplantation , Infertility, Female/prevention & control , Infertility, Male/prevention & control , Adolescent , Allografts , Child , Europe , Female , Humans , Male
8.
Ann Hematol ; 95(8): 1295-305, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27270301

ABSTRACT

Peripheral T cell lymphomas (PTCL) are rare in children and adolescents, and data about outcome and treatment results are scarce. The present study is a joint, international, retrospective analysis of 143 reported cases of non-anaplastic PTCL in patients <19 years of age, with a focus on treatment and outcome features. One hundred forty-three patients, between 0.3 and 18.7 years old, diagnosed between 2000 and 2015 were included in the study. PTCL not otherwise specified was the largest subgroup, followed by extranodal NK/T cell lymphoma, hepatosplenic T cell lymphoma (HS TCL), and subcutaneous panniculitis-like T cell lymphoma (SP TCL). Probability of overall survival (pOS) at 5 years for the whole group was 0.56 ± 0.05, and probability of event-free survival was (pEFS) 0.45 ± 0.05. Patients with SP TCL had a good outcome with 5-year pOS of 0.78 ± 0.1 while patients with HS TCL were reported with 5-year pOS of only 0.13 ± 0.12. Twenty-five percent of the patients were reported to have a pre-existing condition, and this group had a dismal outcome with 5-year pOS of 0.29 ± 0.09. The distribution of non-anaplastic PTCL subtypes in pediatric and adolescent patients differs from what is reported in adult patients. Overall outcome depends on the subtype with some doing better than others. Pre-existing conditions are frequent and associated with poor outcomes. There is a clear need for subtype-based treatment recommendations for children and adolescents with PTCL.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hematopoietic Stem Cell Transplantation/methods , Lymphoma, T-Cell, Peripheral/therapy , Outcome Assessment, Health Care/methods , Adolescent , Child , Child, Preschool , Combined Modality Therapy , Disease-Free Survival , Female , Hematopoietic Stem Cell Transplantation/statistics & numerical data , Humans , Infant , International Cooperation , Male , Remission Induction , Retrospective Studies , Young Adult
9.
Ann Chir Plast Esthet ; 61(1): 23-8, 2016 Feb.
Article in French | MEDLINE | ID: mdl-25708731

ABSTRACT

Surgery is required for phimosis with a contracted fibrous ring or when the medical treatment with steroids has been unsuccessful. Surgical teams often opt for circumcision when a conservative technique can be used. This surgery could have some psychologic consequences, and when the circumcision in not according to religious convictions, it cannot be live well for the patient and his family. Furthermore, some surgery procedures for prepuce conservation seem to give some unaesthesics aspects with cutaneous excess. The objective of this study was to evaluate our new preputioplasty technique according to the initial diagnosis (phimosis with scarred foreskin or long and narrow foreskin), in situation where circumcision is required currently. Outcome evaluated was: easy and painless foreskin retraction, absence of postoperative phimosis as well as cosmetic aspects of the penis. In this study, 90 children benefited from this technique and subsequent follow-up. The mean age was 7.9 years for the 32 children in the sclerotic phimosis group and 6.8 years for the 58 children in the long and narrow foreskin group. We observed complete foreskin retraction without any recurrence in 100% of children with a phimosis resistant to medical treatment which consisted of progressive foreskin retraction and application of topical steroids, with a mean postoperative follow-up of 1.4 years. Results showed an excellent cosmetic aspect of the penis with absence of enlarged foreskin in all our subjects. This study underlines the relevance of this surgical technique.


Subject(s)
Circumcision, Male/methods , Foreskin/surgery , Phimosis/surgery , Child , Child, Preschool , Esthetics , Follow-Up Studies , France , Humans , Male , Prospective Studies , Suture Techniques
10.
Bone Marrow Transplant ; 50(3): 414-9, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25581411

ABSTRACT

Hepatic focal nodular hyperplasia (FNH) is a nonmalignant condition rarely affecting children previously treated for cancer, especially those who received hematopoietic SCT (HSCT). Some aspects of its pathogenesis still remain unclear and a strong association with specific risk factors has not yet been identified. We report here a single institution's case series of 17 patients who underwent HSCT and were diagnosed with FNH, analyzing retrospectively their clinical features and the radiological appearance of their hepatic lesions. We aimed to compare the diagnostic accuracy of ultrasound (US) and magnetic resonance imaging (MRI) and to explore the role of transient elastography (FibroScan) to evaluate the degree of hepatic fibrosis in FNH patients. Our analysis showed an association of FNH with age at transplant ⩽12 years (hazard ratio (HR) 9.10); chronic GVHD (HR 2.99); hormone-replacement therapy (HR 4.02) and abdominal radiotherapy (HR 4.37). MRI proved to be a more accurate diagnostic tool compared with US. Nine out of 12 patients who underwent FibroScan showed hepatic fibrosis. Our study points out that FNH is an emerging complication of HSCT, which requires a lifelong surveillance to follow its course in cancer patients.


Subject(s)
Focal Nodular Hyperplasia/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Adolescent , Child , Child, Preschool , Female , Focal Nodular Hyperplasia/pathology , Hematopoietic Stem Cell Transplantation/methods , Humans , Male , Retrospective Studies , Transplantation Conditioning/adverse effects , Transplantation Conditioning/methods
11.
Bone Marrow Transplant ; 50(2): 181-8, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25387094

ABSTRACT

We analyzed the outcome of 243 children with high-risk (HR) AML in first CR1 enrolled in the AIEOP-2002/01 protocol, who were given either allogeneic (ALLO; n=141) or autologous (AUTO; n=102) hematopoietic SCT (HSCT), depending on the availability of a HLA-compatible sibling. Infants, patients with AML-M7, or complex karyotype or those with FLT3-ITD, were eligible to be transplanted also from alternative donors. All patients received a myeloablative regimen combining busulfan, cyclophosphamide and melphalan; [corrected] AUTO-HSCT patients received BM cells in most cases, while in children given ALLO-HSCT stem cell source was BM in 96, peripheral blood in 19 and cord blood in 26. With a median follow-up of 57 months (range 12-130), the probability of disease-free survival (DFS) was 73% and 63% in patients given either ALLO- or AUTO-HSCT, respectively (P=NS). Although the cumulative incidence (CI) of relapse was lower in ALLO- than in AUTO-HSCT recipients (17% vs 28%, respectively; P=0.043), the CI of TRM was 7% in both groups. Patients transplanted with unrelated donor cord blood had a remarkable 92.3% 8-year DFS probability. Altogether, these data confirm that HSCT is a suitable option for preventing leukemia recurrence in HR children with CR1 AML.


Subject(s)
Cord Blood Stem Cell Transplantation , Hematopoietic Stem Cell Transplantation , Leukemia, Myeloid, Acute/mortality , Leukemia, Myeloid, Acute/therapy , Myeloablative Agonists/administration & dosage , Transplantation Conditioning/methods , Abnormal Karyotype , Adolescent , Allografts , Autografts , Child , Child, Preschool , Disease-Free Survival , Female , Follow-Up Studies , Humans , Infant , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/pathology , Male , Survival Rate , fms-Like Tyrosine Kinase 3/genetics
12.
Rev Sci Instrum ; 85(11): 11E101, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25430280

ABSTRACT

Single crystal Diamond Detectors (SDD) are being increasingly exploited for neutron diagnostics in high power fusion devices, given their significant radiation hardness and high energy resolution capabilities. The geometrical efficiency of SDDs is limited by the size of commercially available crystals, which is often smaller than the dimension of neutron beams along collimated lines of sight in tokamak devices. In this work, we present the design and fabrication of a 14 MeV neutron spectrometer consisting of 12 diamond pixels arranged in a matrix, so to achieve an improved geometrical efficiency. Each pixel is equipped with an independent high voltage supply and read-out electronics optimized to combine high energy resolution and fast signals (<30 ns), which are essential to enable high counting rate (>1 MHz) spectroscopy. The response function of a prototype SDD to 14 MeV neutrons has been measured at the Frascati Neutron Generator by observation of the 8.3 MeV peak from the (12)C(n, α)(9)Be reaction occurring between neutrons and (12)C nuclei in the detector. The measured energy resolution (2.5% FWHM) meets the requirements for neutron spectroscopy applications in deuterium-tritium plasmas.

15.
Leukemia ; 27(2): 416-22, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22907048

ABSTRACT

We studied the prognostic value of minimal disseminated disease (MDD) and anti-ALK immune response in children with NPM-ALK-positive anaplastic-large cell lymphoma (ALCL) and evaluated their potential for risk stratification. NPM-ALK transcripts were analyzed by RT-PCR in bone marrow/peripheral blood of 128 ALCL patients at diagnosis, whereas ALK antibody titers in plasma were assessed using an immunocytochemical approach. MDD was positive in 59% of patients and 96% showed an anti-ALK response. Using MDD and antibody titer results, patients could be divided into three biological risk groups (bRG) with different prognosis: high risk (bHR): MDD-positive and antibody titer ≤ 1/750, 26/128 (20%); low risk (bLR): MDD negative and antibody titer >1/750, 40/128 (31%); intermediate risk (bIR): all remaining patients, 62/128 (48%). Progression-free survival was 28% (s.e., 9%), 68% (s.e., 6%) and 93% (s.e., 4%) for bHR, bIR and bLR, respectively (P<0.0001). Survival was 71% (s.e., 9%), 83% (s.e., 5%) and 98% (s.e., 2%) for bHR, bIR and bLR (P=0.02). Only bHR and histology other than common type were predictive of higher risk of failure (hazard ratio 4.9 and 2.7, respectively) in multivariate analysis. Stratification of ALCL patients based on MDD and anti-ALK titer should be considered in future ALCL trials to optimize treatment.


Subject(s)
Autoantibodies/blood , Lymphoma, Large-Cell, Anaplastic/diagnosis , Neoplasm, Residual/diagnosis , Protein-Tyrosine Kinases/immunology , Receptor Protein-Tyrosine Kinases/metabolism , Adolescent , Anaplastic Lymphoma Kinase , Child , Child, Preschool , Female , Humans , In Situ Hybridization, Fluorescence , Infant , Lymphoma, Large-Cell, Anaplastic/classification , Lymphoma, Large-Cell, Anaplastic/immunology , Lymphoma, Large-Cell, Anaplastic/mortality , Male , Neoplasm, Residual/immunology , Neoplasm, Residual/metabolism , Prognosis , Protein-Tyrosine Kinases/genetics , Protein-Tyrosine Kinases/metabolism , Risk Factors , Survival Rate
16.
Bone Marrow Transplant ; 48(6): 809-13, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23222380

ABSTRACT

To investigate the relationship between clinical response and modification of BK viremia, we assessed retrospectively 32 cases of hemorrhagic cystitis (HC) after allogeneic hematopoietic SCT that were treated with i.v. cidofovir (CDV). They were 22 men (69%) and 10 women (31%) with a median age of 24 years, range 3-62. The median number of CDV doses was 3, range 1-8, and the treatment lasted for a median of 3 weeks, range 1-10. Clinical improvement of HC was observed in 27 patients (84%). In 12 of 32 episodes (37.5%), BK viremia was determined before every CDV administration and a complete clinical response was observed in 10 of 12 patients (83%), the reduction of BK viremia load being 1 log by 2 weeks after starting CDV. Nephrotoxicity related to CDV was observed in nine patients. Among 26 patients with 100-day follow-up, 4 of 4 patients who had a complete clinical response by 30 days were alive vs 16 of 22 (73%) who did not have the resolution of HC in this time frame. We conclude that in patients with HC, the response to CDV treatment is usually associated with a significant reduction of BK viremia load.


Subject(s)
Antiviral Agents/administration & dosage , BK Virus , Cystitis/drug therapy , Cytosine/analogs & derivatives , Hematopoietic Stem Cell Transplantation , Hemorrhage/drug therapy , Organophosphonates/administration & dosage , Polyomavirus Infections/drug therapy , Adolescent , Adult , Allografts , Antiviral Agents/adverse effects , Child, Preschool , Cidofovir , Cystitis/etiology , Cytosine/administration & dosage , Cytosine/adverse effects , Female , Follow-Up Studies , Hemorrhage/etiology , Humans , Infant , Male , Middle Aged , Organophosphonates/adverse effects , Polyomavirus Infections/etiology , Retrospective Studies , Time Factors , Viral Load , Viremia/drug therapy , Viremia/etiology
17.
Rev Sci Instrum ; 84(12): 123505, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24393076

ABSTRACT

Measurements of the response of LaBr3(Ce) to 2.5 MeV neutrons have been carried out at the Frascati Neutron Generator and at tokamak facilities with deuterium plasmas. The observed spectrum has been interpreted by means of a Monte Carlo model. It is found that the main contributor to the measured response is neutron inelastic scattering on (79)Br, (81)Br, and (139)La. An extrapolation of the count rate response to 14 MeV neutrons from deuterium-tritium plasmas is also presented. The results are of relevance for the design of γ-ray diagnostics of fusion burning plasmas.

18.
J Synchrotron Radiat ; 19(Pt 6): 1015-20, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23093764

ABSTRACT

A novel beam position monitor, operated at zero bias voltage, based on high-quality chemical-vapor-deposition single-crystal Schottky diamond for use under intense synchrotron X-ray beams was fabricated and tested. The total thickness of the diamond thin-film beam monitor is about 60 µm. The diamond beam monitor was inserted in the B16 beamline of the Diamond Light Source synchrotron in Harwell (UK). The device was characterized under monochromatic high-flux X-ray beams from 6 to 20 keV and a micro-focused 10 keV beam with a spot size of approximately 2 µm × 3 µm square. Time response, linearity and position sensitivity were investigated. Device response uniformity was measured by a raster scan of the diamond surface with the micro-focused beam. Transmissivity and spectral responsivity versus beam energy were also measured, showing excellent performance of the new thin-film single-crystal diamond beam monitor.

20.
Leukemia ; 26(6): 1375-82, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22289917

ABSTRACT

Understanding the mechanisms that control stress-induced apoptosis is critical to explain how tumours respond to treatment, as cancer cells frequently escape drug toxicity by regulating stress response through heat shock protein (HSP) expression. The overexpression of Hsp72, in particular, results in increased incidence of cell transformation, and correlates with poor prognosis in a wide range of cancers. We have shown that Hsp72 assists folding of oncogenic NPM-ALK kinase in anaplastic large-cell lymphomas (ALCLs), but its role in the maintenance of the malignant phenotype remains uncertain. Therefore, we assessed Hsp72 expression in ALCLs, investigating more in detail the mechanisms that regulate its status and activity. We found that Hsp72 is unique among the HSPs involved in tumourigenesis to be overexpressed in ALK(+) tumours and cell lines and to be induced by stress. Different from other HSPs, Hsp72 prevents cell injury, Bax activation and death by apoptosis in ALK(+) cells, acting both upstream and downstream of mitochondria. Conversely, Hsp72 is underexpressed in ALK(-) ALCL cells, and it is unable to protect cells from apoptosis under stress. Moreover, when Hsp72 expression is reduced following NPM-ALK inhibition, lymphoma cells undergo apoptosis, demonstrating the importance of Hsp72 in regulating ALCL stress response and drug sensitivity.


Subject(s)
Apoptosis , HSP72 Heat-Shock Proteins/metabolism , Lymphoma, Large-Cell, Anaplastic/metabolism , Lymphoma, Large-Cell, Anaplastic/pathology , Mitochondria/pathology , Nuclear Proteins/metabolism , Receptor Protein-Tyrosine Kinases/metabolism , Anaplastic Lymphoma Kinase , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Blotting, Western , Cell Proliferation , Child , Down-Regulation , Gene Expression Profiling , HSP72 Heat-Shock Proteins/genetics , Humans , Immunoenzyme Techniques , Nuclear Proteins/genetics , Nucleophosmin , Oligonucleotide Array Sequence Analysis , Phosphorylation , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Receptor Protein-Tyrosine Kinases/genetics , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Tissue Array Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...